RESUMO
INTRODUCTION: The standard therapy for bronchial asthma consists of combinations of acute (short-acting ß2-sympathomimetics) and, depending on the severity of disease, additional long-term treatment (including inhaled glucocorticoids, long-acting ß2-sympathomimetics, anticholinergics, anti-IL-4R antibodies). The antidepressant amitriptyline has been identified as a relevant down-regulator of immunological TH2-phenotype in asthma, acting-at least partially-through inhibition of acid sphingomyelinase (ASM), an enzyme involved in sphingolipid metabolism. Here, we investigated the non-immunological role of amitriptyline on acute bronchoconstriction, a main feature of airway hyperresponsiveness in asthmatic disease. METHODS: After stimulation of precision cut lung slices (PCLS) from mice (wildtype and ASM-knockout), rats, guinea pigs and human lungs with mediators of bronchoconstriction (endogenous and exogenous acetylcholine, methacholine, serotonin, endothelin, histamine, thromboxane-receptor agonist U46619 and leukotriene LTD4, airway area was monitored in the absence of or with rising concentrations of amitriptyline. Airway dilatation was also investigated in rat PCLS by prior contraction induced by methacholine. As bronchodilators for maximal relaxation, we used IBMX (PDE inhibitor) and salbutamol (ß2-adrenergic agonist) and compared these effects with the impact of amitriptyline treatment. Isolated perfused lungs (IPL) of wildtype mice were treated with amitriptyline, administered via the vascular system (perfusate) or intratracheally as an inhalation. To this end, amitriptyline was nebulized via pariboy in-vivo and mice were ventilated with the flexiVent setup immediately after inhalation of amitriptyline with monitoring of lung function. RESULTS: Our results show amitriptyline to be a potential inhibitor of bronchoconstriction, induced by exogenous or endogenous (EFS) acetylcholine, serotonin and histamine, in PCLS from various species. The effects of endothelin, thromboxane and leukotrienes could not be blocked. In acute bronchoconstriction, amitriptyline seems to act ASM-independent, because ASM-deficiency (Smdp1-/-) did not change the effect of acetylcholine on airway contraction. Systemic as well as inhaled amitriptyline ameliorated the resistance of IPL after acetylcholine provocation. With the flexiVent setup, we demonstrated that the acetylcholine-induced rise in central and tissue resistance was much more marked in untreated animals than in amitriptyline-treated ones. Additionally, we provide clear evidence that amitriptyline dilatates pre-contracted airways as effectively as a combination of typical bronchodilators such as IBMX and salbutamol. CONCLUSION: Amitriptyline is a drug of high potential, which inhibits acute bronchoconstriction and induces bronchodilatation in pre-contracted airways. It could be one of the first therapeutic agents in asthmatic disease to have powerful effects on the TH2-allergic phenotype and on acute airway hyperresponsiveness with bronchoconstriction, especially when inhaled.
Assuntos
Asma , Broncoconstrição , Camundongos , Ratos , Humanos , Animais , Cobaias , Cloreto de Metacolina/farmacologia , Amitriptilina/farmacologia , Amitriptilina/uso terapêutico , Histamina/farmacologia , Broncodilatadores/farmacologia , Broncodilatadores/uso terapêutico , Serotonina/farmacologia , Serotonina/uso terapêutico , Acetilcolina/farmacologia , Simpatomiméticos/farmacologia , Simpatomiméticos/uso terapêutico , 1-Metil-3-Isobutilxantina/farmacologia , 1-Metil-3-Isobutilxantina/uso terapêutico , Dilatação , Pulmão , Asma/tratamento farmacológico , Albuterol , Endotelinas/farmacologia , Endotelinas/uso terapêutico , Tromboxanos/farmacologia , Tromboxanos/uso terapêuticoAssuntos
Asma/tratamento farmacológico , Quimiocina CCL2/metabolismo , Inibidores de Fosfodiesterase/farmacologia , Diester Fosfórico Hidrolases/metabolismo , Pneumonia/tratamento farmacológico , 1-Metil-3-Isobutilxantina/farmacologia , 1-Metil-3-Isobutilxantina/uso terapêutico , Administração por Inalação , Resistência das Vias Respiratórias/efeitos dos fármacos , Resistência das Vias Respiratórias/imunologia , Animais , Asma/diagnóstico , Asma/imunologia , Líquido da Lavagem Broncoalveolar/citologia , Líquido da Lavagem Broncoalveolar/imunologia , Modelos Animais de Doenças , Humanos , Lipopolissacarídeos/imunologia , Masculino , Camundongos , Nebulizadores e Vaporizadores , Ovalbumina/imunologia , Inibidores de Fosfodiesterase/uso terapêutico , Pneumonia/diagnóstico , Pneumonia/imunologia , Transdução de Sinais/efeitos dos fármacos , Transdução de Sinais/imunologia , Organismos Livres de Patógenos Específicos , Volume de Ventilação Pulmonar/efeitos dos fármacos , Volume de Ventilação Pulmonar/imunologiaRESUMO
Chronic exposure to cold caused pulmonary arterial hypertension (cold-induced pulmonary hypertension [CIPH]) and increased phosphodiesterase-1C (PDE-1C) expression in pulmonary arteries (PAs) in rats. The purpose of this study is to investigate a hypothesis that inhibition of PDE-1 would decrease inflammatory infiltrates and superoxide production leading to attenuation of CIPH. Three groups of male rats were exposed to moderate cold (5±1°C) continuously, whereas 3 groups were maintained at room temperature (23.5±1°C, warm; 6 rats/group). After 8-week exposure to cold, 3 groups in each temperature condition received continuous intravenous infusion of 8-isobutyl-methylxanthine (8-IBMX) (PDE-1 inhibitor), apocynin (NADPH oxidase inhibitor) or vehicle, respectively, for 1 week. Cold exposure significantly increased right-ventricular systolic pressure compared with warm groups (33.8±3.2 versus 18.6±0.3 mm Hg), indicating that animals developed CIPH. Notably, treatment with 8-IBMX significantly attenuated the cold-induced increase in right ventricular pressure (23.5±1.8 mm Hg). Cold exposure also caused right-ventricular hypertrophy, whereas 8-IBMX reversed cold-induced right ventricular hypertrophy. Cold exposure increased PDE-1C protein expression, macrophage infiltration, NADPH oxidase activity, and superoxide production in PAs and resulted in PA remodeling. 8-IBMX abolished cold-induced upregulation of PDE-1C in PAs. Interestingly, inhibition of PDE-1 eliminated cold-induced macrophage infiltration, NADPH oxidase activation, and superoxide production in PAs and reversed PA remodeling. Inhibition of NADPH oxidase by apocynin abolished cold-induced superoxide production and attenuated CIPH and PA remodeling. In conclusion, inhibition of PDE-1 attenuated CIPH and reversed cold-induced PA remodeling by suppressing macrophage infiltration and superoxide production, suggesting that upregulation of PDE-1C expression may be involved in the pathogenesis of CIPH.
Assuntos
Temperatura Baixa/efeitos adversos , Nucleotídeo Cíclico Fosfodiesterase do Tipo 1/fisiologia , Hipertensão Pulmonar/enzimologia , Hipertensão Pulmonar/etiologia , 1-Metil-3-Isobutilxantina/uso terapêutico , Acetofenonas/uso terapêutico , Animais , Nucleotídeo Cíclico Fosfodiesterase do Tipo 1/antagonistas & inibidores , Nucleotídeo Cíclico Fosfodiesterase do Tipo 1/biossíntese , Inibidores Enzimáticos/uso terapêutico , Hipertensão Pulmonar Primária Familiar , Hipertensão Pulmonar/tratamento farmacológico , Hipertensão Pulmonar/patologia , Hipertrofia Ventricular Direita/tratamento farmacológico , Hipertrofia Ventricular Direita/enzimologia , Hipertrofia Ventricular Direita/fisiopatologia , Pneumopatias/tratamento farmacológico , Pneumopatias/enzimologia , Pneumopatias/patologia , Macrófagos/efeitos dos fármacos , Macrófagos/enzimologia , Macrófagos/patologia , Masculino , NADPH Oxidases/antagonistas & inibidores , Artéria Pulmonar/efeitos dos fármacos , Artéria Pulmonar/enzimologia , Artéria Pulmonar/fisiopatologia , Ratos , Ratos Sprague-Dawley , Superóxidos/metabolismoRESUMO
Protozoan infections remain a major unsolved medical problem in many parts of our world. A major obstacle to their treatment is the blatant lack of medication that is affordable, effective, safe and easy to administer. For some of these diseases, including human sleeping sickness, very few compounds are available, many of them old and all of them fraught with toxic side effects. We explore a new concept for developing new-generation antiprotozoan drugs that are based on phosphodiesterase (PDE) inhibitors. Such inhibitors are already used extensively in human pharmacology. Given the high degree of structural similarity between the human and the protozoan PDEs, the vast expertise available in the human field can now be applied to developing disease-specific PDE inhibitors as new antiprotozoan drugs.
Assuntos
Antiprotozoários/química , Inibidores de Fosfodiesterase/química , Diester Fosfórico Hidrolases/química , 1-Metil-3-Isobutilxantina/química , 1-Metil-3-Isobutilxantina/farmacologia , 1-Metil-3-Isobutilxantina/uso terapêutico , Sequência de Aminoácidos , Antiprotozoários/farmacologia , Antiprotozoários/uso terapêutico , Sítios de Ligação , Domínio Catalítico , Catecóis/química , Catecóis/farmacologia , Catecóis/uso terapêutico , Humanos , Leishmania major/enzimologia , Dados de Sequência Molecular , Doenças Negligenciadas/tratamento farmacológico , Inibidores de Fosfodiesterase/farmacologia , Inibidores de Fosfodiesterase/uso terapêutico , Diester Fosfórico Hidrolases/classificação , Diester Fosfórico Hidrolases/metabolismo , Alinhamento de Sequência , Trypanosoma brucei brucei/enzimologiaAssuntos
Fibrose Cística , 1-Metil-3-Isobutilxantina/uso terapêutico , Trifosfato de Adenosina/uso terapêutico , Amilorida/uso terapêutico , Aminoglicosídeos , Antibacterianos/uso terapêutico , Fibrose Cística/etiologia , Fibrose Cística/terapia , Regulador de Condutância Transmembrana em Fibrose Cística/genética , Diagnóstico Diferencial , Diuréticos/uso terapêutico , Humanos , Mutação , Inibidores de Fosfodiesterase/uso terapêutico , PrognósticoRESUMO
OBJECTIVE: To examine the effects of topical 3-isobutyl-1-methylxanthine treatment on tear-film osmolarity, conjunctival goblet-cell densities, and corneal epithelial glycogen levels in a rabbit model for keratoconjunctivitis sicca. METHODS: Keratoconjunctivitis sicca was surgically induced in the right eyes of 16 rabbits. In a masked protocol, eight of these operated-on eyes underwent treatment for 12 weeks with a 3.0-mmol solution of 3-isobutyl-1-methylxanthine. The remaining eight operated-on eyes were left untreated and served as controls. RESULTS: The 3-isobutyl-1-methylxanthine treatment resulted in a rapid and significant decrease in tear osmolarity and sodium (P < .5) and potassium levels (P < .05) and a significant increase in conjunctival goblet-cell densities and corneal epithelial glycogen levels compared with untreated and operated-on controls (P < .001). CONCLUSIONS: 3-Isobutyl-1-methylxanthine rapidly and significantly decreased tear-film osmolarity in this rabbit model for keratoconjunctivitis sicca and restored conjunctival goblet-cell densities and corneal glycogen levels, thus reversing the disease process.
Assuntos
1-Metil-3-Isobutilxantina/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Animais , Contagem de Células/efeitos dos fármacos , Túnica Conjuntiva/efeitos dos fármacos , Túnica Conjuntiva/patologia , Córnea/química , Córnea/efeitos dos fármacos , Glicogênio/análise , Ceratoconjuntivite Seca/metabolismo , Ceratoconjuntivite Seca/patologia , Concentração Osmolar , Coelhos , Lágrimas/fisiologiaRESUMO
El presente estudio compara los efectos clínicos y colaterales de dos esquemas de medicación, fenoterol en MDI (micro dosificador inhalatorio) de 100 urg versus fenoterol en MDI de 100 ugr más aminofilina endovenosa, para el tratamiento de crisis de asma leve-moderadas en población pediátrica. Los parámetros evaluados fueron: puntuación de crisis de asma de Bierman-Pierson, frecuencia cardíaca, presencia de tremor, pico espiratorio forzado (PEF). Además se consignó la aparición de otros efectos colaterales, durante un período de 2 horas. Fueron incluídos cincuenta pacientes: veinticinco para cada esquema en forma randomizada. Se encontró que no hubo diferencia significativa entre los grupos de pacientes en cuanto a sus características al ingreso y el efecto clínico del tratamiento, siendo la mejoría en ambos casos similar. Por otro lado el esquema de fenoterol en MDI más aminofilina endovenosa se asoció a un número mayor de efectos adversos, principalmente gastrointestinales. Se observó además que los puntajes clínicos al ingreso constituyen un factor pronóstico para ambos esquemas
Assuntos
Humanos , Masculino , Feminino , Fenoterol/farmacologia , Aminofilina/farmacologia , Estado Asmático/tratamento farmacológico , Nebulizadores e Vaporizadores , 1-Metil-3-Isobutilxantina/uso terapêuticoAssuntos
1-Metil-3-Isobutilxantina/uso terapêutico , Ceratoconjuntivite Seca/tratamento farmacológico , Lágrimas/efeitos dos fármacos , Animais , Contagem de Células , Túnica Conjuntiva/patologia , Córnea/patologia , Epitélio/patologia , Glicogênio/metabolismo , Humanos , Ceratoconjuntivite Seca/patologia , Soluções Oftálmicas , Coelhos , Lágrimas/fisiologiaRESUMO
The pharmacological actions of the new xanthine, isbufylline, were evaluated in several models of airway hyperresponsiveness and airway inflammation in guinea pigs. At a dose (106 mumol kg-1 i.p.) providing complete protection against acetylcholine aerosol-induced dyspnea in the guinea pig, isbufylline inhibited platelet activating factor (PAF)- and antigen-induced eosinophil infiltration into bronchoalveolar lavage fluid 24 h after challenge of normal and actively immunized guinea pigs, respectively. In addition, this dose of isbufylline also inhibited capsaicin-induced extravasation of protein into bronchoalveolar lavage fluid. Isbufylline, 4.2 mumol kg-1 i.v., significantly inhibited PAF-induced bronchial hyper-responsiveness to i.v. histamine, without exerting evident bronchodilator activity. On the other hand the bronchodilator, salbutamol, at a dose (10.4 mumol kg-1 i.p.) shown to be equieffective to isbufylline (106 mumol kg-1 i.p.) for blocking acetylcholine aerosol-induced dyspnea, had no protective action against PAF- or antigen-induced eosinophil recruitment in bronchoalveolar lavage fluid, or against capsaicin-induced plasma protein extravasation. Furthermore, salbutamol (3.5 mumol kg-1) significantly potentiated allergen-induced cell infiltration and PAF-induced bronchial hyperresponsiveness. The results suggest that isbufylline can exert significant anti-inflammatory actions in guinea pig airways, in addition to its bronchodilator activity. These pharmacological activities are not shared by the beta 2-adrenoceptor agonist, salbutamol.
Assuntos
1-Metil-3-Isobutilxantina/análogos & derivados , Hiper-Reatividade Brônquica/tratamento farmacológico , Líquido da Lavagem Broncoalveolar/citologia , Broncodilatadores/farmacologia , Dispneia/prevenção & controle , Leucócitos/efeitos dos fármacos , 1-Metil-3-Isobutilxantina/farmacologia , 1-Metil-3-Isobutilxantina/uso terapêutico , Acetilcolina/farmacologia , Albuterol/farmacologia , Animais , Broncodilatadores/uso terapêutico , Capsaicina/farmacologia , Dextranos , Dispneia/induzido quimicamente , Fluoresceína-5-Isotiocianato/análogos & derivados , Cobaias , Histamina/farmacologia , Masculino , Ovalbumina/toxicidade , Fator de Ativação de Plaquetas/farmacologiaRESUMO
We examined the effect of topically applied 3-isobutyl-1-methylxanthine (IBMX), a known secretagogue, on tear secretion and dry-eye disease in a clinical study. We found that IBMX produced a dose-dependent decrease in tear film osmolarity that was significant at 3.0 mmol/L (P less than .0005) in patients with dry-eye disease. This effect was not blocked by prior administration of proparacaine hydrochloride (P less than .05). Throughout a 4-week, open-label, vehicle-controlled study, IBMX decreased tear film osmolarity significantly, whereas vehicle alone did not. After 4 weeks, mean (+/- SEM) osmolarity in IBMX-treated eyes decreased from 325 +/- 3.2 mOsm/L to 312 +/- 1.8 mOsm/L but remained unchanged in vehicle-treated eyes (323 +/- 4.4 mOsm/L vs 320 +/- 4.2 mOsm/L). In our study, IBMX was significantly more effective than vehicle alone in decreasing rose bengal staining (P less than .02). Hence, topical IBMX stimulated tear secretion and decreased ocular surface disease in patients with dry-eye disease.
Assuntos
1-Metil-3-Isobutilxantina/uso terapêutico , Síndromes do Olho Seco/tratamento farmacológico , Lágrimas/metabolismo , 1-Metil-3-Isobutilxantina/administração & dosagem , Administração Tópica , Adulto , Idoso , Idoso de 80 Anos ou mais , Relação Dose-Resposta a Droga , Feminino , Humanos , Pessoa de Meia-Idade , Concentração Osmolar , Rosa BengalaAssuntos
Anastomose Cirúrgica , Aorta/cirurgia , Artéria Femoral/cirurgia , Oclusão de Enxerto Vascular/prevenção & controle , 1-Metil-3-Isobutilxantina/farmacologia , 1-Metil-3-Isobutilxantina/uso terapêutico , Arteriosclerose/tratamento farmacológico , Arteriosclerose/patologia , Divisão Celular , Colforsina/farmacologia , Colforsina/uso terapêutico , Colágeno/biossíntese , Artéria Femoral/efeitos dos fármacos , Artéria Femoral/patologia , Glicosaminoglicanos/biossíntese , Oclusão de Enxerto Vascular/metabolismo , Oclusão de Enxerto Vascular/patologia , Humanos , Verapamil/farmacologia , Verapamil/uso terapêuticoRESUMO
1. The aim of this study was to compare the effects of the non-selective phosphodiesterase (PDE) inhibitor, isobutylmethylxanthine (IBMX) and the selective PDE III inhibitor, milrinone, in a rabbit model of acute myocardial ischaemia. 2. Coronary artery occlusion caused changes in the ST-segment of the ECG and ectopic activity in all control rabbits. Ventricular fibrillation occurred in 10 out of 14 (71%) of these animals. Pretreatment with IBMX 100 micrograms kg-1 plus 10 micrograms kg-1 min-1, starting 10 min before coronary artery occlusion, reduced ischaemia-induced ST-segment changes and ventricular fibrillation occurred in only 10% of this group (n = 10). A similar dose of milrinone had no antiarrhythmic activity, whereas with a lower dose of milrinone, 30 micrograms kg-1 plus 3 micrograms kg-1 min-1 (n = 10), only 30% of rabbits fibrillated and ST-segment changes were attenuated. 3. Acute administration of both IBMX and milrinone reduced arterial blood pressure. With the higher dose of milrinone a significant effect was still present after 10 min of drug infusion. A greater hypotensive response to the higher dose of milrinone was observed in the rabbits which subsequently fibrillated during ischaemia. A marked tachycardia was also observed after administration of the higher dose of milrinone. 4. At the end of the experiment platelet aggregation was studied ex vivo. ADP-induced aggregation was reduced by pretreatment of the rabbits with milrinone but not IBMX. Both PDE inhibitors enhanced the ability of isoprenaline to inhibit ADP-induced platelet aggregation but milrinone was more effective, particularly at the higher dose. The results demonstrate that IBMX was antiarrhythmic but that this activity was not directly related to inhibition of platelet aggregation. Adverse haemodynamic effects may explain the failure of milrinone to have similar activity during myocardial ischaemia.
Assuntos
1-Metil-3-Isobutilxantina/uso terapêutico , Antiarrítmicos , Arritmias Cardíacas/tratamento farmacológico , Cardiotônicos/uso terapêutico , Doença das Coronárias/complicações , Inibidores de Fosfodiesterase/farmacologia , Agregação Plaquetária/efeitos dos fármacos , Piridonas/uso terapêutico , Teofilina/análogos & derivados , Anestesia , Animais , Arritmias Cardíacas/etiologia , Gasometria , Pressão Sanguínea/efeitos dos fármacos , Doença das Coronárias/fisiopatologia , Eletrocardiografia , Frequência Cardíaca/efeitos dos fármacos , Masculino , Milrinona , Inibidores da Agregação Plaquetária/farmacologia , CoelhosRESUMO
The effect of topical administration of 3-isobutyl-methyl-xanthine (IBMX), a potent phosphodiesterase inhibitor, was studied on an experimentally provoked uveitis in rabbits. After presensitization with an intravitreal injection of human serum albumin (HSA), intravenous antigenic challenge induces blood-aqueous barrier breakdown and leukocyte infiltration. The effect of IBMX on the blood-aqueous barrier was determined by scoring the severity of the flare in the anterior chamber and by determination of the levels of ascorbic acid and protein in the aqueous. Treatment with IBMX 1% two times daily, significantly inhibited the breakdown of the blood-aqueous barrier and the increase in PGE2 level of the aqueous humor. There was no effect on leukocyte infiltration. The therapeutic effect of IBMX in blood-aqueous barrier protection is comparable with the effect of topical treatment with the corticosteroid medrysone.
Assuntos
1-Metil-3-Isobutilxantina/uso terapêutico , Doenças do Sistema Imunitário/tratamento farmacológico , Teofilina/análogos & derivados , Uveíte Anterior/tratamento farmacológico , Animais , Humor Aquoso/citologia , Humor Aquoso/metabolismo , Ácido Ascórbico/metabolismo , Dinoprostona , Proteínas do Olho/metabolismo , Doenças do Sistema Imunitário/imunologia , Doenças do Sistema Imunitário/metabolismo , Contagem de Leucócitos/efeitos dos fármacos , Pregnenodionas/uso terapêutico , Prostaglandinas E/metabolismo , Coelhos , Albumina Sérica/imunologia , Uveíte Anterior/imunologia , Uveíte Anterior/metabolismoAssuntos
1-Metil-3-Isobutilxantina/farmacologia , Neoplasias Experimentais/patologia , Teofilina/análogos & derivados , 1-Metil-3-Isobutilxantina/uso terapêutico , 1-Metil-3-Isobutilxantina/toxicidade , Animais , Divisão Celular/efeitos dos fármacos , Feminino , Neoplasias Pulmonares/tratamento farmacológico , Neoplasias Pulmonares/patologia , Masculino , Camundongos , Metástase Neoplásica , Neoplasias Experimentais/tratamento farmacológicoRESUMO
Local administration of PGE1 to pre-formed inflammatory granulomata of rats results in a decrease of granulomatous tissue and reduction of prostaglandin concentrations in granulomatous exudates. Under the same experimental conditions, a similar correlation between these two effects is observed with dibutyryl cyclic-AMP. An anti-granuloma effect is also achieved with the phosphodiesterase inhibitors, IBMX and RA-233, but not with theophylline, a rather feeble inhibitor of this enzyme. The present findings provide further support for the concept that elevation of cyclic-AMP in cell population(s) within granuloma is a promising line for pharmacological suppression of inflammatory tissue proliferation.